Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia

BMC Infectious Diseases

Maxim L Filipenko²  Tatjana I Petrenko¹  Eugeny A Khrapov³  Olga I Alkhovik¹  Andrey G Cherednichenko¹  Maya A Dymova² 

[1] Ministry of Public Health and Social Development of The Russian Federation (NRIT), Novosibirsk Research Institute of Tuberculosis, Novosibirsk, Russia;Novosibirsk State University (NSU), Novosibirsk, Russia;Institute of Chemical Biology and Fundamental Medicine (ICBFM), Siberian Branch of The Russian Academy of Sciences (SB RAS), Novosibirsk, Russia

关键词: Genotyping;    Drug-resistance mutations;    Multidrug resistance;    Mycobacterium tuberculosis;   

Others  :  1125676
DOI  :  10.1186/1471-2334-14-478

 received in 2013-10-22, accepted in 2014-08-29,  发布年份 2014

【 摘 要 】

Background

The spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis compromises effective control of tuberculosis (TB) in Siberia. Early identification of drug-resistant isolates is, therefore, crucial for effective treatment of this disease. The aim of this study was to conduct drug susceptibility testing and identify mutations in drug resistance genes in clinical isolates of M. tuberculosis from some TB patients presenting for treatment in Siberia.

Methods

Thirty randomly selected clinical isolates of M. tuberculosis were obtained from the Novosibirsk Research Institute of Tuberculosis, Russia. Isolates were screened for drug resistance and characterized by variable number of tandem repeats (VNTR)-typing using 15 standard and four additional loci. Deligotyping on multiple large sequences was performed using 10 loci.

Results

Twenty-nine of the isolates were assigned XDR status. Twenty-eight isolates belonged to the M. tuberculosis Beijing family, from which 11 isolates were considered the M11 type (39%), two the M2 type (7%), and one the M33 type (3%). Seventeen isolates (60.7%) from this family exhibited unique genetic patterns. The remaining two isolates belonged to the Latino-American Mediterranean family. Gene sequences (rpoB, katG, rrs, rpsL, tlyA, gidB, gyrA, gyrB) were analyzed to identify mutations that confer resistance to rifampicin, isoniazid, amikacin, kanamycin, capreomycin, and ofloxacin. The most common mutations among the XDR isolates were S531L in RpoB, S315T in KatG, various codon 94 mutations in gyrA, A90V in GyrA, K43R in RpsL, and 1401 A → G in rrs; these confer resistance to rifampicin, isoniazid, ofloxacin, streptomycin and kanamycin/capreomycin, respectively. There was high congruence between the two typing methods (VNTR typing and deligotyping) and RD105, RD149, RD152, RD181, and RD207 regions of difference were absent from the 28 Beijing family isolates.

Conclusions

Deligotyping can be used for rapid and reliable screening of M. tuberculosis isolates, followed by more in-depth genotyping. Identification of Beijing family isolates with extensive drug resistance confirms that such strains have epidemiological importance in Siberia. Rapid detection of mutations that lead to drug resistance should facilitate selection of effective drug therapies, and the development of early prevention strategies to combat this infection.

【 授权许可】

   
2014 Dymova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: Global Tuberculosis Report. 2012. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf webcite
• [2]Borrell S, Gagneux S: Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009, 13:1456-1466.
• [3]Ramaswamy S, Musser JM: Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998, 79:3-29.
• [4]Nachamkin I, Kang C, Weinstein MP: Detection of resistance to isoniazid, rifampin, and streptomycin in clinical isolates of Mycobacterium tuberculosis by molecular methods. Clin Infect Dis 1997, 24:894-900.
• [5]Maus CE, Plikaytis BB, Shinnick TM: Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005, 49:571-577.
• [6]Van Soolingen D: Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med 2001, 249:1-26.
• [7]Frothingham R, Meeker-O’Connell WA: Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats. Microbiology 1998, 144(Pt 5):1189-1196.
• [8]Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Locht C: Variable human minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol Microbiol 2000, 36:762-771.
• [9]Tsolaki AG, Hirsh AE, DeRiemer K, Enciso JA, Wong MZ, Hannan M, de la Salmoniere YO G, Aman K, Kato-Maeda M, Small PM: Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. Proc Natl Acad Sci U S A 2004, 101:4865-4870.
• [10]Tsolaki Gagneux S, Pym AS, de la Salmoniere YO G, Kreiswirth BN, Van Soolingen D, Small PM: Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis. J Clin Microbiol 2005, 43:1-7.
• [11]Rand WM: Objective criteria for the evaluation of clustering methods. J Am Stat Assoc 1971, 66:846-850.
• [12]Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG: eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 2004, 186:1518-1530.
• [13]Hunter PR, Gaston MA: Numerical index of the discriminatory ability of typing systems: an application of Simpson’s index of diversity. J Clin Microbiol 1988, 26:2465-2466.
• [14]de la Salmoniere YO G, Kim CC, Tsolaki AG, Pym AS, Siegrist MS, Small PM: High-throughput method for detecting genomic-deletion polymorphisms. J Clin Microbiol 2004, 42:2913-2918.
• [15]Allix-Béguec C, Harmsen D, Weniger T, Supply P, Niemann S: Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2008, 46:2692-2699.
• [16]Mazars E, Lesjean S, Banuls AL, Gilbert M, Vincent V, Gicquel B, Tibayrenc M, Locht C, Supply P: High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. Proc Natl Acad Sci U S A 2001, 98:1901-1906.
• [17]Mokrousov I, Narvskaya O, Vyazovaya A, Millet J, Otten T, Vishnevsky B, Rastogi N: Mycobacterium tuberculosis Beijing genotype in Russia: in search of informative variable-number tandem-repeat loci. J Clin Microbiol 2008, 46:3576-3584.
• [18]Mokrousov I: Genetic geography of Mycobacterium tuberculosis Beijing genotype: a multifacet mirror of human history? Infect Genet Evol 2008, 8:777-785.
• [19]Mokrousov I, Ly HM, Otten T, Lan NN, Vyshnevskyi B, Hoffner S, Narvskaya O: Origin and primary dispersal of the Mycobacterium tuberculosis Beijing genotype: clues from human phylogeography. Genome Res 2005, 15:1357-1364.
• [20]Huyen MNT, Kremer K, Lan NTN, Cobelens FGJ, Buu TN, Dung NH, Caws M, Tiemersma EW, van Soolingen D: Mixed tuberculosis infections in rural South Vietnam. J Clin Microbiol 2012, 50:1586-1592.
• [21]Mostrom P, Gordon M, Sola C, Ridell M, Rastogi N: Methods used in the molecular epidemiology of tuberculosis. Clin Microbiol Infect 2002, 8:694-704.
• [22]Dymova MA, Nikonov SD, Akulinushkin AI, Ogirenko AP, Filipenko ML: Mycobacterium tuberculosis Beijing family in Novosibirsk oblast: the prevalence of patients with severe forms of the disease and the connection of multi-drug resistance. Vestn NSU Biol Clin Med 2008, 6(3):106-109.
• [23]Poudel A, Maharjan B, Nakajima C, Fukushima Y, Pandey BD, Beneke A, Suzuki Y: Characterization of extensively drug-resistant Mycobacterium tuberculosis in Nepal. Tuberculosis (Edinb) 2012, 56(6):2831-2836.
• [24]Lasunskaia E, Ribeiro SC, Manicheva O, Gomes LL, Suffys PN, Mokrousov I, Ferrazoli L, Andrade MR, Kritski A, Otten T, Kipnis TL, da Silva WD, Vishnevsky B, Oliveira MM, Gomes HM, Baptista IF, Narvskaya O: Emerging multidrug resistant Mycobacterium tuberculosis strains of the Beijing genotype circulating in Russia express a pattern of biological properties associated with enhanced virulence. Microbes Infect 2010, 12:467-475.
• [25]David S, Portugal C, Antunes A, Cardoso A, Calado A, Barros V, Sancho L: [Molecular identification using Spoligotyping of strains from the Mycobacterium tuberculosis complex isolated from the Hospital Fernando Fonseca]. Rev Port Pneumol 2004, 10:195-204.
• [26]Lipin MY, Stepanshina VN, Shemyakin IG, Shinnick TM: Association of specific mutations in katG, rpoB, rpsL and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia. Clin Microbiol Infect 2007, 13:620-626.
• [27]Billington OJ, McHugh TD, Gillespie SH: Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999, 43:1866-1869.
• [28]Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ: The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science (80- ) 2006, 312:1944-1946.
• [29]Taniguchi H, Aramaki H, Nikaido Y, Mizuguchi Y, Nakamura M, Koga T, Yoshida S: Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett 1996, 144:103-108.
• [30]Bodmer T, Zurcher G, Imboden P, Telenti A: Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995, 35:345-348.
• [31]Ohno H, Koga H, Kohno S, Tashiro T, Hara K: Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother 1996, 40:1053-1056.
• [32]Zhou YN, Jin DJ: The rpoB mutants destabilizing initiation complexes at stringently controlled promoters behave like “stringent” RNA polymerases in Escherichia coli. Proc Natl Acad Sci U S A 1998, 95:2908-2913.
• [33]Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE: Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011, 55:2032-2041.
• [34]Cardoso RF, Cooksey RC, Morlock GP, Barco P, Cecon L, Forestiero F, Leite CQ, Sato DN, Shikama Mde L, Mamizuka EM, Hirata RD, Hirata MH: Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. Antimicrob Agents Chemother 2004, 48:3373-3381.
• [35]Ali A, Hasan R, Jabeen K, Jabeen N, Qadeer E, Hasan Z: Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan. Antimicrob Agents Chemother 2011, 55:5654-5659.
• [36]Ajbani K, Rodrigues C, Shenai S, Mehta A: Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India. J Clin Microbiol 2011, 49:1588-1590.
• [37]Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rüsch-Gerdes S, Niemann S: Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother 2009, 53:3353-3356.
• [38]Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, Liu Y, Nie L, Guo A, Li C: Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol 2008, 46:4075-4077.
• [39]Perdigão J, Macedo R, Malaquias A, Ferreira A, Brum L, Portugal I: Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother 2010, 65:224-227.
• [40]Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM: Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A 1997, 94:9869-9874.
• [41]Gutierrez MC, Ahmed N, Willery E, Narayanan S, Hasnain SE, Chauhan DS, Katoch VM, Vincent V, Locht C, Supply P: Predominance of ancestral lineages of Mycobacterium tuberculosis in India. Emerg Infect Dis 2006, 12:1367-1374.
• [42]Kalinda AS, Aldrich CC: Pyrazinamide: a frontline drug used for tuberculosis: molecular mechanism of action resolved after 50 years? ChemMedChem 2012, 7:558-560.
• [43]Evans J, Segal H: Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother 2010, 65:897-900.
• [44]Baldeviano-Vidalón GC, Quispe-Torres N, Bonilla-Asalde C, Gastiaburú-Rodriguez D, Pro-Cuba JE, Llanos-Zavalaga F: Multiple infection with resistant and sensitive M. tuberculosis strains during treatment of pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2005, 9:1155-1160.